Market Pulse

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

AirAsia  in India

AirAsia in India

AirAsia India launch seen in Q4; may order 50 more Airbus jets: CEO.  Full Article 

Jet, Spicejet Results

Jet, Spicejet Results

Jet Airways, SpiceJet report quarterly losses.  Full Article | Related Story 

Tata Steel Shines

Tata Steel Shines

Tata Steel surges; Q4 operating profit beats f'cast.  Full Article 

Gold Outlook

Gold Outlook

Gold faces more pressure as inflation stays tame.  Full Article 

RBI's May Review

RBI's May Review

Subbarao overrules panel view on rate action in May.  Full Article 

Steel Output

Steel Output

Jindal to expand steel output, buy mines in West Africa.  Full Article 

Abe's Agenda

Abe's Agenda

Special Report - The deeper agenda behind "Abenomics".  Full Article 

Revenge of Markets

Revenge of Markets

For months, markets have been dancing to central bankers' tune, but that may now be changing, writes James Saft.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Novartis gets U.S. approval to buy Fougera

Stocks

   

Mon Jul 16, 2012 10:32pm IST

* Novartis must give up rights to three medicinal creams

* Fougera will be folded into Sandoz generics unit

WASHINGTON, July 16 (Reuters) - Swiss drugmaker Novartis has won U.S. antitrust approval to close its purchase of generic dermatology products maker Fougera.

The Federal Trade Commission said on Monday that as a condition of approval, Novartis agreed to give up the rights to market three topical skin care medicines made by Tolmar Inc and to cancel a deal for a fourth.

Novartis said in May that it would buy Fougera for $1.53 billion from a consortium of private equity funds led by Nordic Capital, DLJ Merchant Banking and Avista Capital Partners.

The three generic creams that Novartis must give up marketing rights to are a topical solution to treat psoriasis, a local anesthetic, and a cream to treat rosacea, which causes chronically red skin, the FTC said.

In addition to generic dermatology products, Fougera also has a branded specialty pharmaceuticals business. It had 2011 sales of $429 million.

Fougera, based in Melville, New York, will be folded into Novartis' Sandoz generics unit.

A spokeswoman for Novartis was not immediately available to comment on Monday.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.